Storia in 2 fonti

ASCO26: Cancer vaccines and at-home injectable drugs continue to show promise

A number of companies presented new data on their cancer vaccine candidates at ASCO 2026.

Raccontata da

pharmaceutical-technology.com

biopharmadive.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

pharmaceutical-technology.comStai leggendo3 mesi fa

ASCO26: Cancer vaccines and at-home injectable drugs continue to show promise

A number of companies presented new data on their cancer vaccine candidates at ASCO 2026.

originale

biopharmadive.com3 mesi fa

ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer

At the year’s biggest cancer meeting, a high-stakes clash between two popular drug classes erupted, and scientists made headway against a once-insurmountable foe.

Leggi questa versione → originale

Timeline cronologica

lunedì 1 giugno 2026·pharmaceutical-technology.com
ASCO26: BMS and J&J debut shining multiple myeloma data - Pharmaceutical Technology
Both BMS and J&J touted positive data for their multiple myeloma drugs at ASCO 2026.
lunedì 1 giugno 2026·pharmaceutical-technology.com
ASCO 2026: key readouts in lung cancer - Pharmaceutical Technology
At ASCO 2026, companies debuted data that could hold the potential to disrupt the frontline treatment paradigm for various subtypes of NSCLC.

ASCO26: Cancer vaccines and at-home injectable drugs continue to show promise

ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer

Timeline cronologica

ASCO26: BMS and J&J debut shining multiple myeloma data - Pharmaceutical Technology

ASCO 2026: key readouts in lung cancer - Pharmaceutical Technology

ASCO26: Cancer vaccines and at-home injectable drugs continue to show promise

ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer

ASCO26: In vivo oncology approaches continue to show promise